{
    "data": [
        {
            "id": "4307300",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-17T12:56:07-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Comparing 'FANG' Stocks With 'MADGAG', Also We Closed S&P At 3,120; My Top: 3,150; Hedge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "82017",
                            "type": "sentiment"
                        },
                        {
                            "id": "82018",
                            "type": "sentiment"
                        },
                        {
                            "id": "82019",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4307300-comparing-fang-stocks-madgag-also-closed-s-and-p-3120-top-3150-hedge"
            }
        },
        {
            "id": "4306122",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-13T07:26:09-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences Is A Buy Taking Into Account Patent Dynamics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "81836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "80390",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4306122-edwards-lifesciences-is-buy-taking-account-patent-dynamics"
            }
        },
        {
            "id": "4300298",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-30T09:00:33-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Thoughts On Its Growth Plans And Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "77648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4300298-edwards-lifesciences-thoughts-on-growth-plans-and-valuation"
            }
        },
        {
            "id": "4291362",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-13T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cash In On Edwards Lifesciences Before Its Leadership Premium Is Lost",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105432",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "64869",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4291362-cash-in-on-edwards-lifesciences-leadership-premium-is-lost"
            }
        },
        {
            "id": "4277012",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-24T10:02:06-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences Beats, Raises And Surges: Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "54625",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4277012-edwards-lifesciences-beats-raises-and-surges-analysis"
            }
        },
        {
            "id": "4264106",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-15T00:55:12-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: A Med-Tech Stock Staying Strong For A Reason",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "37829",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264106-edwards-lifesciences-med-tech-stock-staying-strong-for-reason"
            }
        },
        {
            "id": "4258559",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-01T12:58:43-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Assessing The Next Moves",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34804",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4258559-edwards-lifesciences-assessing-next-moves"
            }
        },
        {
            "id": "4248059",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-12T12:03:15-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Medical Devices Stock Price Gain Opportunity: Edwards Lifesciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23348",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4248059-medical-devices-stock-price-gain-opportunity-edwards-lifesciences"
            }
        },
        {
            "id": "4242541",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-20T14:09:46-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: It's Expensive, But It's Recession-Proof",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104958",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8777",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4242541-edwards-lifesciences-expensive-recession-proof"
            }
        }
    ]
}